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Newly determined crystal structures suggest that the
membrane-binding C2 domains of blood coagulation
cofactors Va and VIIIa bind anionic phospholipids
through protruding solvent-exposed hydrophobic
residues, aided by a crown of positively charged
residues and by specific hydrogen-bonding side chains.
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The blood coagulation cascade is activated in response to
vascular damage and culminates in the generation of throm-
bin at sites of injury, resulting in the formation of a blood
clot composed of platelets and fibrin. Thrombin is gener-
ated by the prothrombinase complex consisting of coagula-
tion cofactor Va, a non-enzymatic cofactor; factor Xa, a
serine protease; phospholipid membranes and calcium
(Figure 1). Factor X is proteolytically activated to factor Xa
by a similar complex, the so-called tenase complex which
consists of coagulation cofactor VIIIa, factor IXa, phospho-
lipids and calcium (Figure 1). Inherited deficiencies of the
coagulation factors are important causes of blood disorders
— for example, a deficiency of factor VIII causes hemo-
philia A, while a deficiency of factor V causes
parahemophilia [1]. Factors V and VIII have very similar
sequences and the same subunit organization, with six
major domains in the sequence A1–A2–B–A3–C1–C2. Upon
cofactor activation, the B domain is removed by limited pro-
teolysis catalysed by either factor Xa or thrombin [1].
The prothrombinase and tenase complexes bind anionic
phospholipid membranes, especially those containing
phosphatidyl-L-serine; this binding increases the catalytic
efficiency of the respective serine proteases by three to five
orders of magnitude. Phospholipids are believed to concen-
trate substrates and enzymes in space, increasing the rate of
productive cleavage, and also to facilitate two-dimensional
transfer of coagulation factors between the various com-
plexes (Figure 1). In human platelet membranes, anionic
phosphatidylserine lipids are sequestered in the inner
membrane layer, whereas neutral phospholipids such as
sphingomyelin and phosphatidylcholine form the outer
layer. This asymmetry in lipid distribution is maintained
by an ATP-dependent amino-phospholipid translocase.
On activation of blood platelets and blood cells by throm-
bin, this translocase activity is blocked and a calcium-
dependent lipid ‘scramblase’ randomizes exposure of
phosphatidylserine and phosphatidylethanolamine on the
cell surface, generating a procoagulant surface for the pro-
thrombinase and tenase complexes [2]. The preference for
naturally occurring phosphatidyl-L-serine, rather than phos-
phatidyl-D-serine, implies a stereospecific recognition of
phospholipids by cofactors Va and VIIIa [3,4].
Cofactors Va and VIIIa bind to anionic phospholipids, in a
Ca2+-independent manner, through their light chains.
These binding reactions have apparent dissociation
constants in the nanomolar range, and there is little or no
effect of ionic strength in relevant physiological
conditions. The available evidence suggests that the C2
domain of each cofactor mediates this binding, although a
contribution from the A3 domain of cofactor Va has been
suggested. A mechanism for the interaction between these
two C2 domains and phospholipid membranes has now
been proposed on the basis of their recently determined
crystal structures [5,6].
Structural analysis of cofactor C2 domains
In both factor V and factor VIII, the C2 domain fold is a
distorted jelly-roll β barrel, divided into one five-
stranded and one three-stranded β sheet (Figure 2a).
The global shape is a cylinder of about 45 Å in length
Figure 1
Protein components of the blood coagulation cascade. (a) The
phospholipid-bound tenase complex — cofactor VIIIa, activated factor
IX and factor X — proteolytically cleaves factor X to form the
activated factor X. The activated factor X serine protease then
assembles with cofactor Va and II to form the pro-thrombinase
complex, which in turn cleaves factor II to release thrombin (factor
IIa). (b) Cofactors Va and VIIIa each have a heavy chain (green) of
homologous domains A1 and A2, and a light chain (purple) made up
of a third A domain (A3) followed by two C domains (C1 and C2).
Sequence numbers — for cofactor Va above and cofactor VIIIa below
— refer to amino acids in the uncleaved polypeptides. Crystal
structures have now been determined for the C2 domains of both
cofactors Va and VIIIa [5,6].
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and 30 Å in diameter. In both sequence and structure,
these C2 domains belong to the discoidin family of
binding proteins [7], and are quite different from the C2
domains of protein kinase C, phospholipases and synap-
totagmin, despite their similar phospholipid-binding
properties and nomenclature.
The crystallographic structures of the C2 domains of factor
V and factor VIII [5,6] are similar to each other, with a root-
mean-square deviation of 0.5 Å for the backbone atoms of
core residues (which show 43% sequence identity), and also
to earlier models of C2 structures [8,9] that were based on
the homologous substrate-binding domain of galactose
oxidase [10], another member of the discoidin family. The
strong structural homology between the substrate-binding
domain of galactose oxidase and the C2 domains is unusual
— the observed root-mean-square deviation of 2 Å between
the backbone atoms in the protein core would imply a
sequence identity of 27% [11], whereas the actual sequence
identity is less than 15% [8,9]. This shows that, despite
extremely low sequence identity, structural similarity can
be successfully identified by a careful analysis of protein
sequences in the context of a known structural template.
Binding to anionic phospholipids
A striking feature of the C2 domain structures is that, in
three distinct areas, hydrophobic residues stand out and
are exposed to the solvent (Figure 2). In two protruding
β-hairpin loops at one end of the β barrel (Figures 2a,b),
these side chains — methionine 2199, phenylalanine 2200
and leucines 2251 and 2252 in factor VIII, and tryptophans
2063 and 2064 and leucine 2116 in factor V — are
proposed to participate in membrane binding by insertion
into the phospholipid bilayer [5,6,8,9]. The third area —
involving prolines 2299 and 2300 and leucine 2302 in
factor VIII, and prolines 2166 and 2167 and isoleucine
2169 in factor V — is located at the opposite end of the C2
domain cylinder, near the amino and carboxyl termini and
probably interacts with the C1 domain [6,9].
The first β-hairpin loop has a slightly different conforma-
tion in factor VIII, where it is formed by residues
2196–2203, and factor V, where it is formed by residues
2060–2067 (Figure 2a). But this β-hairpin loop also
adopts two different conformations — referred to as
‘closed’ and ‘open’ — in the two crystal forms of the
factor V C2 domain [5]. The authors speculate that the
closed confor-mation, with tryptophan 2064 sequestered
from solvent, reflects the plasma-circulating state of
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Figure 2
Stereo views of the C2 domains of cofactors VIII and V. (a) A ribbon
diagram of the factor VIII C2 domain shows the eight-stranded β-barrel
divided into three-stranded (lime green) and five-stranded (red)
antiparallel β-sheets. A disulfide bond (purple, top left) connects the
amino and carboxyl termini. Two β-hairpins (green) protrude off the
bottom of the β-barrel, and expose hydrophobic side chains — red for
factor VIII and green for factor V — which are proposed to insert into the
phospholipid bilayer. The thin lines, red for factor VIII and green for
factor V, represent the proposed orientation of C2 domains relative to a
membrane. (b) Superposed crystallographic structures of the factor VIII
C2 domain (red) and both the open (green) and closed (light gray)
conformations of the factor V C2 domain. The largest difference in loop
conformations occurs in the first β-hairpin loop (bottom right) that
contains the proposed membrane-anchoring residues. Disulfide
bridges are shown in red for factor VIII and green for factor V (open
conformation). (c) Superposed C2 domain structures of factor VIII and
factor V (open conformation), showing the proposed
membrane-binding motifs that include solvent-exposed hydrophobic
side chains (red for factor VIII, green for factor V) and a crown of
positively charged residues located around the surface of the factor VIII
(purple) and factor V (cyan) C2 domains. The view is rotated by 90°
from the plane of the paper compared to those in panels (a) and (b).
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factor V, while the open conformation, with tryptophan
2064 solvent exposed, reflects the protein’s membrane-
binding state. Unless specified, we shall compare the
open form of the factor V C2 to the factor VIII C2
domain. In the structure of the factor VIII C2 domain [6],
an additional solvent-exposed hydrophobic side chain
can be seen, that of valine 2223, which is also proposed to
participate in phospholipid binding.
Both the factor V and factor VIII C2 domains have overall
positive charges — +11 and +4, respectively. Positive
electrostatic potential is scattered all over the domain
surface [9,10], but the structures [5,6] show that several
positively charged side chains form a crown (Figure 2c).
From molecular modelling analysis, we earlier suggested [9]
that the solvent-exposed hydrophobic residues and the
crown of positively charged residues together form the
phospholipid-binding sites of the C2 domains. This
suggestion is supported by the two crystal structures [5,6]. 
Solvent-exposed hydrophobic residues have also been
observed on other membrane-binding proteins, including
the phosphatidylserine-binding domain of vitamin
K-dependent coagulation factors [2], and the annexin V
molecule [12]. Hydrophobic anchorage into the phospho-
lipid membrane explains the minor effect that calcium
ion concentration has on membrane binding by factor V
and factor VIII. But the large overall positive charge of
the C2 domains may drive the binding toward anionic
phospholipids, explaining the apparent complexity of
factor V binding to the membrane and the difficulty in
analyzing it [13].
The structure of the factor V C2 domain [5] provides more
detailed predictions about phosphatidylserine binding.
The authors have proposed specific atomic interactions
between one or two phosphatidylserine head groups and
residues located in a groove enclosed between the two
protruding β-hairpin loops that carry exposed hydrophobic
side chains. If a complex of factor V and phospholipid
head groups can be co-crystallized, determination of its
structure should further our understanding of how the
protein specifically binds phosphatidyl-L-serine. 
The proposed membrane-binding orientations of the two
C2 domains are shown in Figure 2a. The factor VIII C2
domain is tilted relative to the factor V C2 domain
because of the additional solvent-exposed hydrophobic
residue valine 2223. From a recent electron crystallogra-
phy analysis at 15 Å resolution, however, the long axis of
the factor VIII C2 domain was suggested to be perpendic-
ular to the phospholipid membrane [14]. The new crystal
structures [5,6] will allow additional site-directed mutants
to be designed and characterized in the hope of further
refining the correct orientations of the C2 domains with
respect to the phospholipid membranes.
Mutational analysis
More than 250 missense mutations in factor VIII are
known to cause hemophilia A [15]. The available crystal
structures [5,6] and molecular modeling techniques have
made possible a detailed analysis of the structural effects of
known mutations in the C2 domain. In the case of the factor
VIII C2 domain, the structural consequences of 21 muta-
tions were analysed by Pratt et al. [6] and ourselves [16]. For
the most part, the conclusions drawn from these two analy-
sis are in agreement. For instance, on the basis of molecular
modelling and conservation of the residue throughout the
discoidin family, we suggested [16] that a mutation of argi-
nine 2209 — on the large loop between β strands 1 and 2 —
would have a structural effect. The crystal structure of the
factor VIII  C2 domain [6] confirmed that this residue has
an important structural role as a result of its participation in
an extensive hydrogen bond network.
There is, however, a difference worth noting between the
two sets of conclusions [6,16]. Pratt et al. [6] suggested
that, because they lack an obvious structural role, solvent-
exposed residues tryptophan 2229, arginine 2304 and argi-
nine 2307 may be involved in protein–protein interactions,
possibly with von Willebrand factor. But these residues
are highly conserved in the discoidin family of protein
domains, suggesting that they do have a structural role in
this protein family. That they also have a structural role in
the factor VIII C2 domain is supported by the observation
that mutation of arginine 2307 to either glutamine or
leucine causes a defect in secretion of the protein from
cells in which it is produced [17] — secretory defects of
this kind are commonly caused by mutations that disrupt
protein folding. Further experimental studies and analysis
are required to unravel the roles of these residues in the
factor VIII molecule.
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